E
Evan Tzanis
Researcher at Pfizer
Publications - 43
Citations - 892
Evan Tzanis is an academic researcher from Pfizer. The author has contributed to research in topics: Methylnaltrexone & Omadacycline. The author has an hindex of 12, co-authored 38 publications receiving 644 citations.
Papers
More filters
Journal ArticleDOI
Subcutaneous Methylnaltrexone for Treatment of Opioid-Induced Constipation in Patients With Chronic, Nonmalignant Pain: A Randomized Controlled Study
Edward Michna,E. Richard Blonsky,Seth Schulman,Evan Tzanis,Amy Manley,Haiying Zhang,Shrividya Iyer,Bruce Randazzo +7 more
TL;DR: Data is presented demonstrating that subcutaneous methylnaltrexone 12 mg given once daily (QD) or every other day provides significant relief of OIC and was generally well tolerated in patients with chronic, nonmalignant pain.
Journal ArticleDOI
Omadacycline for Community-Acquired Bacterial Pneumonia
Roman Stets,Monica Popescu,Joven Gonong,Ismail Mitha,William Nseir,Andrzej Madej,Courtney Kirsch,Anita Das,Lynne Garrity-Ryan,Judith N. Steenbergen,Amy Manley,Paul B. Eckburg,Evan Tzanis,Paul C. McGovern,Evan Loh +14 more
TL;DR: Omadacycline was noninferior to moxifloxacin for the treatment of community‐acquired bacterial pneumonia in adults and investigator‐assessed clinical response at a post‐treatment evaluation 5 to 10 days after the last dose.
Journal ArticleDOI
Omadacycline for Acute Bacterial Skin and Skin-Structure Infections
William O'Riordan,Sinikka Green,J Scott Overcash,Ivan Puljiz,Symeon Metallidis,J Gardovskis,Lynne Garrity-Ryan,Anita Das,Evan Tzanis,Paul B. Eckburg,Amy Manley,Stephen Villano,Judith N. Steenbergen,Evan Loh +13 more
TL;DR: Omadacycline was noninferior to linezolid for the treatment of acute bacterial skin and skin‐structure infections and had a similar safety profile.
Journal ArticleDOI
Comparison of Omadacycline and Tigecycline Pharmacokinetics in the Plasma, Epithelial Lining Fluid, and Alveolar Cells of Healthy Adult Subjects.
Mark H. Gotfried,Karolyn S. Horn,Lynne Garrity-Ryan,Stephen Villano,Evan Tzanis,Surya Chitra,Amy Manley,S. Ken Tanaka,Keith A. Rodvold +8 more
TL;DR: The pharmacokinetic advantages of higher and sustained concentrations of omadacycline compared to those of tigecycline in plasma, ELF, and AC suggest that omadACYcline is a promising antibacterial agent for the treatment of lower respiratory tract bacterial infections caused by susceptible pathogens.
Journal ArticleDOI
Safety and efficacy of methylnaltrexone in shortening the duration of postoperative ileus following segmental colectomy: results of two randomized, placebo-controlled phase 3 trials.
Chang Sik Yu,Ho-Kyung Chun,Nancy Stambler,Jennifer Carpenito,Seth Schulman,Evan Tzanis,Bruce Randazzo +6 more
TL;DR: Intensive methylnaltrexone at doses of 12 mg and 24 mg was safe, in general, and well tolerated in postcolectomy patients, and the utility of intravenous methylnALTrexone in treating postoperative ileus remains unproven.